A third option is suppression: the United States would forgo development of ASI and stop anyone else from building it on the basis that superintelligence is just too dangerous to be unleashed on the ...

We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...

Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

A macOS ClickFix campaign shifted tactics from openly serving infostealer lures to hiding them behind a browser-fingerprinting gate. The change makes malicious infrastructure harder to detect while ...